By Michal Nitka (Teva)2025-08-14T11:24:43
In this article, Michal Nitka, Senior Vice President, Head of Generics Europe & Global Head OTC, Teva Pharmaceuticals, outlines how policy reform, digital innovation, and manufacturing resilience can secure sustainable access to essential treatments - ensuring generic medicines remain a cornerstone of equitable, reliable care.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-02-19T15:00:00 2026-02-19T16:00:00
Sponsored by Veolia
2025-12-03T07:58:01
Sponsored by MBV AG
2026-03-26T15:00:00 2026-03-26T16:00:00
Sponsored by Medable
2026-05-12T07:43:00
Sponsored by Sartorius, By European Pharmaceutical Review
2025-12-11T13:32:00
Sponsored by Hexagon
Site powered by Webvision Cloud